bullish
Otsuka Holdings (4578 JP): Revenue Guidance Raise and New Products Line-Up Enhance Conviction
279 Views27 Jul 2022 17:24
SUMMARY
- Otsuka Holdings (4578 JP) has raised revenue guidance for H1FY23 by 6%, due to continued strong performance of its four global brands, which contribute more than 35% of total revenue.
- However, the company has cut operating and net profit guidance for H1FY23, mainly due to one-off charge related to elimination of unrealized gains on inventories caused by yen depreciation.
- Otsuka received positive CHMP opinion for lupus nephritis drug, Lupkynis. This will pave the way for gaining marketing approval of the drug in Europe.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Otsuka Holdings (4578 JP): Global Products Continue to Shine; Second Consequent 2023 Guidance Raise04 Nov 2023
- Otsuka Holdings (4578 JP): Strong 1H23 Result Prompts 2023 Guidance Raise; Pipeline Is Advancing13 Sep 2023
- Otsuka Holdings (4578 JP): Strong 2022 Result; 2023 Revenue to Hit Record-High Thanks to Key Drugs08 Apr 2023
- Otsuka Holdings (4578 JP): Revenue Guidance Raise and New Products Line-Up Enhance Conviction27 Jul 2022
- Otsuka Holdings (4578 JP) 1Q22: Global Products Continued Double-Digit Revenue Growth25 May 2022
- Otsuka Holdings (4578 JP): Well-Diversified Portfolio to Augment Revenue Growth08 Oct 2021
x